Last reviewed · How we verify
HDM2005
At a glance
| Generic name | HDM2005 |
|---|---|
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma (PHASE1, PHASE2)
- A Study of HDM2005 in Patients With Advanced Solid Tumor (PHASE1)
- A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDM2005 CI brief — competitive landscape report
- HDM2005 updates RSS · CI watch RSS
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI